Defining the Clinical Course of Multiple Sclerosis.

Slides:

Advertisements

Similar presentations

Inflammation and Neurodegeneration in Multiple Sclerosis

Advertisements

OBJECTIVES: 1.To become empowered and educated to gain control over a disease where you feel no control. 2.To identify the basic outcome measure that you.

Guidelines for a standardized MRI protocol for MS:

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Dayna Ryan, PT, DPT Winter  Primarily known as a disease of CNS myelin (demyelination)  Recent evidence shows early involvement of CNS axons as.

© 2014 Direct One Communications, Inc. All rights reserved. 1 The Current Clinical Arena of Progressive Multiple Sclerosis Carrie M. Hersh, DO Mellen Center.

Overview of Multiple Sclerosis  Valerie Robinson, D.O. 

But Why the Red Sox? Principles and Practice of Assistive Technology Massachusetts Institute of Technology October 26, 2011 Robert J. Mendoza, Psy.D.

Multiple Sclerosis Brett Glover Paramedic ’08 5/26/08.

FREEDOMS II TRIAL.

Multiple Sclerosis Abdulelah Nuqali Intern. DemyelinationCNSAquired Multiple Sclerosis Optic neuritis Acute Disseminated Encephalomyelitis Hereditary.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 23 Drugs for Multiple Sclerosis.

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-blind, Placebo-controlled Trial Aaron E. Miller,

Multiple Sclerosis BY: SARAH BURGESS. “For every male that is diagnosed with multiple sclerosis there is three women diagnosed”

Multiple sclerosis James parker. What is multiple sclerosis Multiple sclerosis is a It is a chronic disease affecting more women than men often leading.

Adam Percey. What is it?  MS is a disease of the central nervous system.  What happens is the myelin sheaths around the axon of a nerve fade away. These.

Multiple Sclerosis Brett Catlin Period Seven September 3 rd, 2003.

© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.

Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.

MS: A Perspective on the African American Experience Mary D. Hughes, MD Medical Director, Neuroscience Associates University Medical Group Greenville Hospital.

Multiple Sclerosis. Incidence 85,000 patient in UK Cases present between 20-40yrs of age Twice as many females Not a fatal condition, most patients have.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Natalizumab and Dimethyl Fumarate: A Fresh Take on Pivotal Trials and Reports from Ongoing.

“Of MS and Men” Morbidity & Mortality Outcomes Mitchell T. Wallin, MD, MPH MS Clinic Director Department of Veterans Affairs Medical Center Washington,

Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.

Laquinimod, a Once-Daily Oral Drug in Development for The Treatment of Relapsing–Remitting Multiple Sclerosis Stephen Krieger, MD Assistant Professor of.

EXEMPLAR OF MULTIPLE SCLEROSIS INTRODUCTION AND ASSESSMENT.

Clinical features, disease course and prognosis in patients with paediatric And young adult onset multiple sclerosis. Paolo Ragonese, Maria Antonietta.

Long-term Efficacy Data for Psychiatric Drugs Rationale for Long-Term Treatment Earl Giller, MD, PhD Pfizer Global Research & Development Long-Term Efficacy.

Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.

Clinico-Radiological Profile of Spinal Cord Multiple Sclerosis Glenn H. Roberson Bhavik N. Patel Asim K. Bag University of Alabama at Birmingham, Birmingham,

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Anti-CD25 Antibody Daclizumab in the Inhibition.

Multiple Sclerosis (MS) a serious, chronic and debilitating disease What is MS? A disease of the brain and spinal cord.

STUDY ON THE LEVELS OF TAU AND β-AMYLOID IN CSF OF PATIENTS WITH MULTIPLE SCLEROSIS Levente Szalárdy MD Department of Neurology University of Szeged Hungary.

Orienting network dysfunction in progressive multiple sclerosis (ID 208) Chalah MA 1,2, Palm U 1,3, Nguyen R 1,4, Créange A 1,4, Lefaucheur JP 1,2, Ayache.

CATEGORY: IMMUNE DYSFUNCTION Multiple Sclerosis Lindsay Nicholson, University of Bristol, UK [ Multiple sclerosis (MS) is.

Four Known Types of MS Clinically isolated syndrome (CIS)

NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.

Nat. Rev. Neurol. doi: /nrneurol

Multiple Sclerosis.

Brain health: time matters in multiple sclerosis

Compared with multiple sclerosis (MS), progressive multifocal leukoencephalopathy (PML) is more likely to produce large, confluent lesions on T2-weighted.

Characteristic time courses for various neurologic disorders

Belle Huffman Biology 430 Dr. Spilatro

Figure 1 Perivenous distribution of multiple sclerosis lesions

Nat. Rev. Neurol. doi: /nrneurol

Stephen L. Hauser, Jorge R. Oksenberg Neuron

Figure 3 Archetypal MS clinical course depicted over 20 years

Figure 3 Example of venous narrowing

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 1 Evolution of multiple sclerosis

Fluid-attenuated inversion recovery magnetic resonance imaging at the onset of the clinical investigation (A, B) and 2 months later (C, D). Fluid-attenuated.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 1 Characteristics of the German National MS Cohort

In 507 follow-up images, only 1

Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.

Figure 2 Example of venous narrowing

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

New Insights into Multiple Sclerosis Clinical Course from the Topographical Model and Functional Reserve Stephen C. Krieger, MD, James Sumowski, PhD

Figure 1 Anti-Epstein-Barr virus nuclear antigen-1 IgG quartile antibody status differences in MRI measures Anti-Epstein-Barr virus nuclear antigen-1 IgG.

Figure 2 Summary of the utility of MOG-Abs and OCB testing in predicting pediatric disease course at onset compared to clinical follow-up at 1 yearFollowing.

Figure 1 Levels of miR-150 are elevated in patients with multiple sclerosis (MS) and patients with clinically isolated syndrome (CIS) who convert to MS.

Figure 1 Full-length MOG cell-based assay using a serum dilution of 1:160 as a cutoff for positivity (red line in both plots)(A) Myelin olidgodendrocyte.

Figure 4 Four representative disease-course archetypes

Figure A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia.

Figure 2 Clinical data and variation of sNfL levels of patients 4–6 with ATZ-treated MS Clinical data and variation of sNfL levels of patients 4–6 with.

Figure 2 Time from incident ADS event to MS diagnosis

Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Presentation transcript:

Defining the Clinical Course of Multiple Sclerosis

1996 Multiple Sclerosis Clinical Subtypes Subtype Description Relapsing-remitting MSFull recovery from relapses or residual deficit after incomplete recovery Secondary progressive MSProgressive accumulation of disability after initial relapsing course, with/without occasional relapses and minor remissions Primary progressive MSProgressive accumulation of disability from onset, with/without temporary plateaus, minor remissions, and improvements Progressive relapsing MSProgressive accumulation of disability from onset but clear acute clinical attacks with/without full recovery Lublin FD, et al. Neurology. 1996; 46:

2013 MS Phenotype Modifications Definitions Disease activity – Relapses; acute/subacute episodes of new/increasing neurological dysfunction, followed by full/partial recovery – New contrast-enhancing T1 hyperintense or new/ enlarging T2 hyperintense lesions Disease progression – Increasing, objectively documented neurologic dysfunction/ disability without recovery (fluctuations and periods of stability may occur) – Imaging not yet established/standardized Lublin FD, et al. Neurology. 2014;83:278–286.

2013 MS Phenotype Modifications Worsening Disease/Disease Progression Worsening disease: Relapsing forms of MS – Documented increase in neurologic dysfunction/disability as a result of relapses or progressive disease Disease progression: Progressive forms of MS – Reserved for worsening disease in those solely in a progressive phase of disease Confirmed worsening/progression – Increase of neurologic dysfunction confirmed throughout a specified time interval – “Sustained progression” should no long be used, as neurologic dysfunction may still improve, even if progression is confirmed Lublin FD, et al. Neurology. 2014;83:278–286

2013 Multiple Sclerosis Clinical Subtypes Subtype Modifications Clinically isolated syndrome Not active Active (transitioning to MS) Relapsing-remitting MS Not active Active Primary progressive MS Active and with progression Active but without progression Not active but with progression Not active and without progression Secondary progressive MS Active and with progression Active but without progression Not active but with progression Not active and without progression Lublin FD, et al. Neurology. 2014;83:278–286.